Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 7Phase 3 6Phase 1/2 5Phase NA 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Endocrine 6Gastrointestinal 1

Conditions

Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 6lanreotide 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2pasireotide 2fluorodopa F 18 2Temozolomide 2Lutetium-177 2Lutetium 2Introns 2Ga(III)-DOTATOC 2telotristat ethyl 1pembrolizumab 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Watchful Waiting 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × lutetium Lu 177 dotatate × NET × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Sinotau Pharmaceutical Group

Phase 3 Active not recruiting
196 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
166 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Jules Bordet Institute

Phase 3 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡